Skip to main content

U.S. government aims at high insulin prices with plan for $35 copay in Medicare

By Reuters  
   March 11, 2020

The Trump administration on Wednesday turned back to its pledge to fight high U.S. drug prices with a plan to limit the out-of-pocket cost for insulin, a life-saving medicine, to $35 per month for many people with diabetes who are enrolled in Medicare.

Full story

Get the latest on healthcare leadership in your inbox.